1. Chifotides H.T., & Dunbar K.R. (2005). Interactions of Metal−Metal-Bonded Antitumor Active Complexes with DNA Fragments and DNA. Acc. Chem. Res., 38, 146-156.
2. Bednarski P.J., Mackay F.S., & Sadler P.J. (2007). Photoactivatable platinum complexes. Anticancer Agents Med. Chem., 7, 75-93.
3. Rose M.J., Fry N.I., Maelow R., Hinck L., & Manscharak P.K. (2008). Sensitization of Ruthenium Nitrosyls to Visible Light via Direct Coordination of the Dye Resorufin: Trackable NO Donors for Light-Triggered NO Delivery to Cellular Targets. J. A. Chem. Soc., 130, 8834-8846.
4. Lippert B., (1999). Cisplatin: Chemistry and Biochemistry of a leading Anticancer Drug. Zürich: Verlag Helvetica Chimica Acta, Weinheim, New York, Wiley-VCH,
5. Allardyce C.S., & Dyson P.J. (2001). Ruthenium in medicine: Current clinical uses and future prospects. Platinium Met. Rev., 45, 62-69
6. Nori A., & Kopecek J. (2005). Intracellular targeting of polymer-bound drugs for cancer chemotherapy. Adv. Drug. Deliv. Rev., 57, 609-636.
7. Shi M., Ho K., Keating A., & Shoichet M.S. (2009). Doxorubicin‐Conjugated Immuno‐Nanoparticles for Intracellular Anticancer Drug Delivery. Adv. Funct. Mater., 19, 1689-1696.
8. Habtermariam A., Melchart M., Ernandez R., Parsons S., Oswald I.D.H, Parkin A., Fabbiani F.P.A., Davidson J.E, Dawson A., Aird R.E, Jodrell D.I., & Sadler P.J. (2006). Structure-activity relationships for cytotoxic ruthenium(II) arene complexes containing N,N-, N,O-, and O,O-chelating ligands. J. Med. Chem. 49, 6858-6868.
9. Chem W.J., Guo P., Song J., Cao W., & Bian J. (2006). The ortho hydroxy-amino group: another choice for synthesizing novel antioxidants. Bioorg. Med. Chem. Lett., 16, 3582-3585.
10. Sathiyaraj S., Sampath K., Butcher R.J., & Jayabalakrishnan C. (2013). Synthesis, DNA binding, antioxidant and cytotoxic activities of ruthenium (II) complexes of a Schiff base ligand. Transition Met. Chem. 38, 291-298.
11. Ramesh R., & Sivagamasundari M. (2003). Synthesis, spectral and antifungal activity of Ru (II) mixed‐ligand complexes. Synth. React. Inorg. Met. Org. Chem., 33, 899-910.
12. Maurya R.C., Patel P., & Rajput S. (2003). Synthesis and Characterization of N‐(o‐Vanillinidene)‐p‐anisidine and N, N′‐bis (o‐Vanillinidene) ethylenediamine and Their Metal Complexes. Synth. React. Inorg. Met. Org. Chem., 23, 817-836.
13. Nakamoto K. (1971). Infrared and Raman spectra of Inorganic and Co-ordination compounds. Wiley Interscience, New York.
14. Sathiyaraj S., Butcher R.J., & Jayabalakrishnan C. (2012). Synthesis, characterization, DNA interaction and in vitro cytotoxicity activities of ruthenium(II) Schiff base complexes. J. Mol. Struct., 1030, 95-103.
15. Sharma R.K., Singh R.V., & Tandon J.P. (1980). Biscyclopentadienyl titanium(IV) complexes of monofunctional bidentate ketamines,. J. Inorg. Nucl. Chem., 42, 1382-1384.
16. Cambell M.J.M. (1975). Transition metal complexes of thiosemicarbazide and thiosemicarbazones. Coord. Chem. Rev. 15, 279-319.
17. Ballhausen C.J. (1962). Ligand Field Theory. Mc Graw Hill, New York,
18. Chichak K., Jacquemard U., & Brande N.R. (2002). The Construction of (Salophen)ruthenium(II) Assemblies Using Axial Coordination. Eur. J. Inorg. Chem., 2002, 357-368.
19. Ramesh R., Maheswaran S. (2003) Synthesis, spectra, dioxygen affinity and antifungal activity of Ru (III) Schiff base complexes. J. Inorg. Biochem. 96 457-462.
20. Prabhakaran R., Geetha A., Thilagavathi M., Karvembu R., Krishna V., Bertagnolli H., & Natarajan K. (2004). Synthesis, characterization, EXAFS investigation and antibacterial activities of new ruthenium(III) complexes containing tetradentate Schiff base. J. Inorg. Biochem., 98, 2131-2140.
21. Perz S., Lopez C., Caubet A., Solans X., Bardia M.F., Gich M., & Molins E. (2007). Versatility in the mode of coordination {(N), (N,O)−, (C,N)−or (C,N,O)2−} of [(η5C5H5)Fe{(η5-C5H4)–CH=N–(C6H4-2OH)}] to palladium(II). J. Organomet. Chem., 692, 2402-2414.
22. Long E.C., Barton K. (1990). On demonstrating DNA intercalation. Acc. Chem. Res., 23, 271-273.
23. Chitrapriya N., Mahalingam V., Zeller M., & Natarajan K. (2010). Synthesis, characterization, crystal structures and DNA binding studies of nickel(II) hydrazone complexes. Inorg. Chim. Acta., 363, 3685-3693.
24. Kamatchi T.S., Chitrapriya N., Lee H., Fronczek C.F., Fronczek F.R., & Natarajan K. (2012). Ruthenium (II)/(III) complexes of 4-hydroxy-pyridine-2, 6-dicarboxylic acid with PPh3/AsPh3 as co-ligand: impact of oxidation state and co-ligands on anticancer activity in vitro. Dalton Trans., 41, 2066-2077.
25. Sathiyaraj S., Sampath K., Butcher R.J., Pallepogu R., & Jayabalakrishnan C. (2013). Designing, structural elucidation, comparison of DNA binding, cleavage, radical scavenging activity and anticancer activity of copper(I) complex with 5-dimethyl-2-phenyl-4-[(pyridin-2-ylmethylene)-amino]-1,2-dihydro-pyrazol-3-one Schiff base ligand. Eur. J. Med. Chem., 64, 81-89.
26. Matesanz A.I., Hernandez C., Rodriguez A., & Souza P. (2011). 3,5-Diacetyl-1,2,4-triazol bis(4N-substituted thiosemicarbazone) palladium(II) complexes: Synthesis, structure, antiproliferative activity and low toxicity on normal kidney cells. J. Inorg. Biochem., 105, 1613-1622.
27. Chatt J., Leigh G.J., Mingos D.M.P., & Paske R.J. (1968). Complexes of osmium, ruthenium, rhenium, and iridium halides with some tertiary monophosphines and monoarsines. J. Chem. Soc. (A), 2636-2641.
28. Poddar R.K., Khullar I.P., & Agarwala U. (1974) Some ruthenium(III) complexes with triphenylarsine. Inorg. Nucl. Chem. Lett., 10, 221-227.
29. Natarajan K., Poddar R.K., & Agarwala U. (1977). Mixed complexes of ruthenium(III) and ruthenium(II) with triphenylphosphine or triphenylarsine and other ligands. J. Inorg. Nucl. Chem., 39, 431-435.
30. Wolf A., Shimer G.H., & Meehan T. (1987). Polycyclic aromatic hydrocarbons physically intercalate into duplex regions of denatured DNA. Biochem. 26, 6392-6396.
31. Elizabeth K., & Rao M.N.A. (1990). Oxygen radical scavenging activity of curcumin. Int. J. Pharmaceut. 58, 237-240.
32. Yu W., Zhao Y., & Shu B. (2004). The radical scavenging activities of Radix purariae isoflavanoids: A chemiluminescence study. Food chem. 86, 525-529.
33. Blagosklonny M., & EL-Diery W.S. (1996). In vitro evaluation of a p53‐expressing adenovirus as an anti‐cancer drug. Int. J. Cancer, 67, 386-392.